Auriemma, Renata Simona (2017) Pituitary aggressive tumors and carcinomas: epidemiological, molecular, clinical, radiological, pathological and therapeutic characterization. [Tesi di dottorato]
Anteprima |
Testo
Auriemma RS-PhD Thesis.pdf Download (2MB) | Anteprima |
| Tipologia del documento: | Tesi di dottorato |
|---|---|
| Lingua: | English |
| Titolo: | Pituitary aggressive tumors and carcinomas: epidemiological, molecular, clinical, radiological, pathological and therapeutic characterization |
| Autori: | Autore Email Auriemma, Renata Simona renatasimona.auriemma@unina.it |
| Data: | 7 Aprile 2017 |
| Numero di pagine: | 115 |
| Istituzione: | Università degli Studi di Napoli Federico II |
| Dipartimento: | Medicina Clinica e Chirurgia |
| Dottorato: | Terapie avanzate medico-chirurgiche |
| Ciclo di dottorato: | 29 |
| Coordinatore del Corso di dottorato: | nome email Di Minno, Giovanni diminno@unina.it |
| Tutor: | nome email Pivonello, Rosario [non definito] |
| Data: | 7 Aprile 2017 |
| Numero di pagine: | 115 |
| Parole chiave: | Pituitary aggressive tumors |
| Settori scientifico-disciplinari del MIUR: | Area 06 - Scienze mediche > MED/13 - Endocrinologia |
| Informazioni aggiuntive: | Tutor: Prof Rosario Pivonello rosario.pivonello@unina.it |
| Depositato il: | 27 Apr 2017 09:45 |
| Ultima modifica: | 14 Mar 2018 11:54 |
| URI: | http://www.fedoa.unina.it/id/eprint/11596 |
| DOI: | 10.6093/UNINA/FEDOA/11596 |
Abstract
Knowledge about epidemiological, clinical, molecular and pathological characteristics of pituitary aggressive tumors and carcinomas is still scant, and strong evidence about the best therapeutic approach is yet to be achieved. The current study has confirmed pituitary carcinomas to be exceptionally rare, but highlighted that atypical tumors might be more common than previously thought. Apart from the clear-cut definition of atypical and malignant pituitary tumors, based on WHO criteria and on the presence of distant metastases, respectively, nowadays tumors size, recurrence, laterosellar extension and responsiveness to conventional medical treatments appear to be the best clinical and radiological criteria to discriminate pituitary tumors with a true aggressive behavior. Conversely, tumor invasiveness is not a good predictor of tumor aggressiveness and cannot discriminate pituitary atypical and malignant tumors from typical and benign adenomas. Radiotherapy and medical treatments remain the most commonly used therapeutic approaches for pituitary aggressive tumors, but fail to induce the achievement of disease control in most patients. Experience with new target therapies, such as pasireotide and everolimus, is still scant, however in vitro data support the use of combined treatment with pasireotide and everolimus as potential valid alternative treatment in patients with aggressive pituitary tumors poorly responsive to conventional medical treatments. Drug responsiveness can be, however, influenced by specific tumor receptor eterogeneity, tachyphylaxis or other factors influencing drug effectiveness, such as somatostatin receptors and mTOR components expression profile, and in turn early identification of molecular markers able to predict responsiveness to treatment might drive endocrinologists through the choice of the best individualized adjuvant therapy in patients with pituitary aggressive tumors and carcinomas.
Downloads
Downloads per month over past year
Actions (login required)
 |
Modifica documento |
